• Type of Event: The document is the transcript of the Q2 FY 2026-27 Earnings Conference Call, hosted by ICICI Securities Limited.
  • Date and Time: The call was held on Friday, November 6, 2026. A specific start time was not mentioned in the transcript.
  • Purpose: The purpose of the call was to discuss the company's financial results for the quarter and half year ended September 30, 2026, and to provide an update on the integration of the recently acquired TruBridge business.
  • Management Participants: The following management representatives participated:
  • Mr. Sachin K. Gupta – Founder and Global Chief Executive Officer
  • Ms. Nithya Balasubramanian – Whole-Time Director & Chief Financial Officer
  • Mr. Saransh Mundra – Head, Investor Relations
  • Availability of Materials: The transcript of the call was made available on the company's website at the provided link: <https://ikshealth.com/ir/2027/q2/transcript-q2.pdf>.
  • UPSI Statement: The document is a disclosure of the earnings call transcript pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The call itself contained forward-looking statements, and a standard disclaimer was provided, advising discretion for investment decisions.

Financial and Strategic Highlights

  • Financial Period Discussed: Q2 and H1 FY 2026-27 (Quarter and Half Year ended September 30, 2026).
  • Key Financial Figures:
  • Revenue: INR 1,592.5 crores (USD ~$169 million), representing 104% YoY growth and 78% QoQ growth in rupee terms.
  • EBITDA: INR 442 crores, with a margin of 27.8%.
  • Adjusted EBITDA (excluding ESOP expenses): INR 459 crores.
  • PBT: INR 273 crores (20% YoY growth).
  • PAT: INR 217 crores.
  • Adjusted PAT (excluding non-cash items): INR 273 crores (17% of revenue, 36% YoY growth).
  • Operating Cash Flow (adjusted): INR 393 crores (~90% conversion of EBITDA).
  • Net Debt: INR 5,280 crores (approx. $550 million).
  • Business Segmentation:
  • Legacy IKS Business (incl. AQuity): Revenue run rate of ~$385 million. Q2 revenue was ~$101 million, representing ~13% YoY growth in USD terms. EBITDA margins were maintained at ~34.5-35%.
  • Legacy TruBridge Business: Revenue run rate of ~$300 million. Q2 revenue was ~$68 million (consolidated for 82 days). Presynergy EBITDA is in line with expectations.
  • TruBridge Integration Update: Management provided a detailed update on the integration, highlighting five key dimensions:

1. People & Culture: Three of TruBridge's top five executives have taken leadership roles in the combined entity.

2. EHR Stickiness: The EHR business is described as highly sticky, with customers eager for modernization.

3. Data Access: Access to patient records for AI training is 3.5x-4x higher than the initial assumption of 5 million.

4. Synergy Potential: Early analysis suggests margin synergy opportunities are better than expected.

5. Cross-Sell Demand: Strong demand exists within the TruBridge install base for IKS's system of action offerings.

  • Growth Strategy & Outlook:
  • The legacy IKS business is expected to continue growing above the industry rate of ~12%.
  • FY27 is a year of "consolidation and stabilization" for TruBridge, with significant growth expected to begin in FY28.
  • A strategy was outlined to build an "AI-native operating system" (Project Endeavor) for the rural/community market by integrating system of record and system of intelligence.
  • Three IKS system of action features (denial prediction/prevention, coding, clinical documentation/virtual assistant) are prioritized for integration into the TruBridge EHR by Q1 FY28.
  • The long-term "True North" target remains INR 3,000 crores EBITDA by FY2030, with a goal to reduce net leverage to near zero.
  • ESOP Grant: An ESOP grant of ~4% of total equity to ~65 top leaders is anticipated, with 80% performance-linked to the FY2030 EBITDA target. The financial impact will be disclosed and modeled from Q3 FY27 onwards.
  • New Customer Wins: The company reported four new wins in the legacy IKS business (Augusta Health, White-Wilson, Evolve, UMass Memorial) and one new TruBridge customer (MISH).

Additional Notes Section

  • The document is a regulatory filing containing the full transcript of the earnings conference call.
  • The transcript includes a full question-and-answer session with analysts, covering topics such as margin synergy levers, growth trajectory, debt repayment, and product integration details.
  • No standalone financial data (e.g., a full income statement or balance sheet) was disclosed within this transcript; it is a commentary on previously released results.